In the article by J. Baselga et al., which appeared in the July 1, 1998 issue of Cancer Research (pp. 2825–2831), there are typographical errors in the scales of the vertical axis of Figures 2 and 3. In Figure 2 and Figure 3A, the numbers on the vertical axis should have read “0–1–2–3–4–5–6,” instead of “0–10–20–30–40–50–60.” In Figure 3B and FIG 3C, the numbers on the vertical axis should have read “0–0.2–0.4–0.6–0.8–1,” instead of “0–2–4–6–8–10–12 ….” The corrected figures are reprinted below.
Activity of rhuMAb HER2 (HER2) against well established BT-474 tumor xenografts in athymic mice in two separate experiments. A, rhuMAb HER2 was given i.p. twice a week for 4 weeks at doses of 1, 10, and 30 mg/kg. The control group was treated with a nonspecific rhuMAb IgG at a dose of 30 mg/kg. RhuMAb HER2 at doses equal to or greater than 1 mg/kg markedly suppressed the growth of BT-474 xenografts. B, in this experiment lower doses of rhuMAb HER2 were used to define whether rhuMAB HER2 had a dose- response relationship. RhuMAb HER2 was given i.p. twice a week for 5 weeks at doses of 0.1, 0.3, and 1 mg/kg. The control group was treated with nonspecific rhuMAb IgG at a dose of 1 mg/kg. At these dose levels, rhuMAb HER2 induced a dose- dependent inhibition of growth of the BT-474 xenografts. Results are given as mean tumor vol-ume + SE. Arrows show days on which treatment was administered.
Activity of rhuMAb HER2 (HER2) against well established BT-474 tumor xenografts in athymic mice in two separate experiments. A, rhuMAb HER2 was given i.p. twice a week for 4 weeks at doses of 1, 10, and 30 mg/kg. The control group was treated with a nonspecific rhuMAb IgG at a dose of 30 mg/kg. RhuMAb HER2 at doses equal to or greater than 1 mg/kg markedly suppressed the growth of BT-474 xenografts. B, in this experiment lower doses of rhuMAb HER2 were used to define whether rhuMAB HER2 had a dose- response relationship. RhuMAb HER2 was given i.p. twice a week for 5 weeks at doses of 0.1, 0.3, and 1 mg/kg. The control group was treated with nonspecific rhuMAb IgG at a dose of 1 mg/kg. At these dose levels, rhuMAb HER2 induced a dose- dependent inhibition of growth of the BT-474 xenografts. Results are given as mean tumor vol-ume + SE. Arrows show days on which treatment was administered.
A, antitumor activity of rhuMAb HER2 (HER2) in combination with paclitaxel (TAX) or doxorubicin (doxo) against well established BT-474 tumor xonografts in athymic mice. The control group was treated with the control rhuMAb IgG, 0.3 mg/kg twice weekly i.p. RhuMAb HER2 was given i.p. twice a week for 5 weeks at a dose of 0.3 mg/kg. Paclitaxel was given i.v. at a dose of 10 mg/kg on days 1 and 4. Doxorubicin was administered i.p. at a dose of 10 mg/kg body weight on day 1. Doxorubicin and paclitaxel, given each in combination with the control antibody, resulted in an equipotent, but modest, antitumor activity. The combined treatment with rhuMAb HER2 plus either paclitaxel or doxorubicin resulted in a marked enhancement of the antitumor effects of both chemotherapeutic agents, with greater inhibition of tumor growth in the group of animals treated with paclitaxel and rhuMAb HER2. B, antitumor activity of rhuMAb HER2 (HER2) in combination with two dose levels of paclitaxel (TAX) against well established BT-474 tumor xenografts in athymic mice. The control group was treated with the nonspecific rhuMAb IgG 0.3 mg/kg twice weekly i.p. RhuMAb HER2 was given at a dose of 0.3 mg/kg i.p. twice a week for 5 weeks and paclitaxel was given i.v. at two dose levels: 5 and 10 mg/kg on days 1 and 4. Treatment with rhuMAb HER2 resulted in a modest inhibition of growth. Treatment with paclitaxel resulted in a dose-dependent inhibition of growth with greater inhibition of growth at the 10 mg/kg dose level than at the 5 mg/kg dose level. RhuMAb HER2 plus paclitaxel resulted in a striking inhibition of growth regardless of the dose of paclitaxel. C, antitumor activity of rhuMAb HER2 (HER2) in combination with repeated doxorubicin (doxo) administration. The control group was treated with PBS. RhuMAb HER2 was given i.p. twice a week for 4 weeks at doses of 0.3 mg/kg, and doxorubicin was given i.p. at a dose of 3.75 mg/kg body weight (days 1 and 2) and repeated on days 14 and 15. RhuMAb HER2 enhanced the antitumor activity of doxorubicin although the combined therapy was not statistically superior than doxorubicin alone or rhuMAb HER2 alone (see text). Results are given as mean tumor volume + SE. Arrows show days on which treatment was administered.
A, antitumor activity of rhuMAb HER2 (HER2) in combination with paclitaxel (TAX) or doxorubicin (doxo) against well established BT-474 tumor xonografts in athymic mice. The control group was treated with the control rhuMAb IgG, 0.3 mg/kg twice weekly i.p. RhuMAb HER2 was given i.p. twice a week for 5 weeks at a dose of 0.3 mg/kg. Paclitaxel was given i.v. at a dose of 10 mg/kg on days 1 and 4. Doxorubicin was administered i.p. at a dose of 10 mg/kg body weight on day 1. Doxorubicin and paclitaxel, given each in combination with the control antibody, resulted in an equipotent, but modest, antitumor activity. The combined treatment with rhuMAb HER2 plus either paclitaxel or doxorubicin resulted in a marked enhancement of the antitumor effects of both chemotherapeutic agents, with greater inhibition of tumor growth in the group of animals treated with paclitaxel and rhuMAb HER2. B, antitumor activity of rhuMAb HER2 (HER2) in combination with two dose levels of paclitaxel (TAX) against well established BT-474 tumor xenografts in athymic mice. The control group was treated with the nonspecific rhuMAb IgG 0.3 mg/kg twice weekly i.p. RhuMAb HER2 was given at a dose of 0.3 mg/kg i.p. twice a week for 5 weeks and paclitaxel was given i.v. at two dose levels: 5 and 10 mg/kg on days 1 and 4. Treatment with rhuMAb HER2 resulted in a modest inhibition of growth. Treatment with paclitaxel resulted in a dose-dependent inhibition of growth with greater inhibition of growth at the 10 mg/kg dose level than at the 5 mg/kg dose level. RhuMAb HER2 plus paclitaxel resulted in a striking inhibition of growth regardless of the dose of paclitaxel. C, antitumor activity of rhuMAb HER2 (HER2) in combination with repeated doxorubicin (doxo) administration. The control group was treated with PBS. RhuMAb HER2 was given i.p. twice a week for 4 weeks at doses of 0.3 mg/kg, and doxorubicin was given i.p. at a dose of 3.75 mg/kg body weight (days 1 and 2) and repeated on days 14 and 15. RhuMAb HER2 enhanced the antitumor activity of doxorubicin although the combined therapy was not statistically superior than doxorubicin alone or rhuMAb HER2 alone (see text). Results are given as mean tumor volume + SE. Arrows show days on which treatment was administered.
RSS Feeds